Chemomab Therapeutics (CMMB) files Q3 2025 financial update

Rhea-AI Filing Summary

Chemomab Therapeutics Ltd. filed a Form 6-K as a foreign private issuer to furnish a press release titled “Chemomab Therapeutics Announces Third Quarter 2025 Financial Results and Provides a Corporate Update.” The press release is attached as Exhibit 99.1.

The company states that Exhibit 99.1 is incorporated by reference into its existing registration statements on Form F-3 and Form S-8. The report is signed on behalf of Chemomab by Chief Financial Officer Sigal Fattal.

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of November 2025

Commission File Number 001-38807

CHEMOMAB THERAPEUTICS LTD.
(Translation of registrant’s name into English)

10 Habarzel Street, Building C, 10th Floor, Tel-Aviv, Israel

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.

Form 20-F ☒           Form 40-F ☐

EXPLANATORY NOTE

Chemomab Therapeutics Ltd. (the “Company”) hereby furnishes under this Report of Foreign Private Issuer on Form 6-K (the “Form 6-K”) the following: (i)  press release, dated November 20, 2025, titled “Chemomab Therapeutics Announces Third Quarter 2025 Financial Results and Provides a Corporate Update” as Exhibit 99.1 to this Form 6-K.

Exhibit 99.1 to this Report on Form 6-K shall be deemed to be incorporated by reference into Company’s Registration Statements on Form F-3 (File No. 333-275002 and No. 333-281750) and Form S-8 (File No. 333-259489 and No. 333-266868).

EXHIBIT INDEX

Exhibit		Description
99.1		Press Release dated November 20, 2025, titled “Chemomab Therapeutics Announces Third Quarter 2025 Financial Results and Provides Corporate Update"

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	CHEMOMAB THERAPEUTICS LTD.
Date: November 21, 2025	By:	/s/ Sigal Fattal
		Sigal Fattal
		Chief Financial Officer

FAQ

What does Chemomab Therapeutics (CMMB) report in this Form 6-K?

Chemomab Therapeutics uses this Form 6-K to furnish a press release on its third quarter 2025 financial results and a corporate update. The press release is attached as Exhibit 99.1 and formally submitted to U.S. investors through this filing.

What is Exhibit 99.1 in Chemomab Therapeutics November 2025 Form 6-K?

Exhibit 99.1 is a press release dated November 20, 2025 titled “Chemomab Therapeutics Announces Third Quarter 2025 Financial Results and Provides Corporate Update.” It contains the detailed financial results and corporate information referenced in the Form 6-K cover text.

How is Chemomabs Q3 2025 press release used in its SEC registrations?

Chemomab specifies that Exhibit 99.1 to the Form 6-K is incorporated by reference into its registration statements on Form F-3 and Form S-8. This allows the information in the press release to form part of those existing registration documents.

Which Chemomab SEC registration statements incorporate this Form 6-K by reference?

The company states that Exhibit 99.1 is incorporated by reference into its Form F-3 registration statements with file numbers 333-275002 and 333-281750, and its Form S-8 registration statements with file numbers 333-259489 and 333-266868.

Who signed Chemomab Therapeutics November 2025 Form 6-K?

The Form 6-K is signed on behalf of Chemomab Therapeutics Ltd. by Sigal Fattal, the companys Chief Financial Officer. The signature block is dated November 21, 2025, confirming the companys authorization of the submission.

What period does the Chemomab Therapeutics November 2025 Form 6-K relate to?

The filing relates to the third quarter of 2025. It furnishes a press release titled “Chemomab Therapeutics Announces Third Quarter 2025 Financial Results and Provides a Corporate Update,” indicating the period covered by the underlying financial and corporate information.